MCF Advisors LLC Acquires New Stake in CRISPR Therapeutics AG (NASDAQ:CRSP)

MCF Advisors LLC bought a new position in CRISPR Therapeutics AG (NASDAQ:CRSP) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 2,037 shares of the company’s stock, valued at approximately $80,000.

Several other hedge funds have also recently made changes to their positions in CRSP. Highline Wealth Partners LLC purchased a new stake in CRISPR Therapeutics in the 4th quarter worth about $39,000. Wilmington Savings Fund Society FSB bought a new stake in shares of CRISPR Therapeutics in the third quarter valued at approximately $40,000. Darwin Wealth Management LLC purchased a new stake in shares of CRISPR Therapeutics during the 3rd quarter valued at approximately $43,000. Eastern Bank purchased a new position in CRISPR Therapeutics in the 3rd quarter valued at approximately $70,000. Finally, AdvisorNet Financial Inc raised its holdings in CRISPR Therapeutics by 91.1% during the 4th quarter. AdvisorNet Financial Inc now owns 2,478 shares of the company’s stock valued at $98,000 after acquiring an additional 1,181 shares during the period. 69.20% of the stock is currently owned by institutional investors.

CRISPR Therapeutics Trading Up 6.5 %

Shares of CRISPR Therapeutics stock opened at $44.20 on Thursday. The business has a fifty day simple moving average of $44.43 and a two-hundred day simple moving average of $47.88. The firm has a market capitalization of $3.77 billion, a P/E ratio of -15.62 and a beta of 1.68. CRISPR Therapeutics AG has a 12 month low of $36.52 and a 12 month high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.42) by $0.41. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. The business had revenue of $0.60 million during the quarter, compared to the consensus estimate of $6.65 million. During the same quarter last year, the firm earned ($1.41) earnings per share. Analysts predict that CRISPR Therapeutics AG will post -5.13 earnings per share for the current year.

Insider Buying and Selling at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 15,000 shares of the stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $55.10, for a total transaction of $826,500.00. Following the sale, the chief executive officer now owns 181,540 shares in the company, valued at $10,002,854. This represents a 7.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 4.10% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of analysts recently issued reports on CRSP shares. Barclays decreased their price objective on CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating on the stock in a research note on Wednesday, November 6th. Needham & Company LLC restated a “buy” rating and issued a $84.00 price objective on shares of CRISPR Therapeutics in a research report on Tuesday, January 14th. Bank of America decreased their target price on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. JMP Securities reissued a “market outperform” rating and issued a $86.00 price target on shares of CRISPR Therapeutics in a report on Friday, December 20th. Finally, StockNews.com raised shares of CRISPR Therapeutics to a “sell” rating in a report on Monday, December 30th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $78.38.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.